Inovio clinches $16.17m financing:
This article was originally published in Clinica
Executive Summary
Inovio Biomedical (San Diego, California) has secured $16.17m in the sale of common stock to institutional and accredited investors in Singapore and North America. The company, a specialist in drug delivery devices based on electroporation, sold around 4.6 million shares at $3.52 per share, in a bid to raise additional financing to fund the further development of its DNA delivery technology for gene-based therapies. The sale price represents an approximate 7% discount in comparison to Inovio's closing share price on the date of the definitive sales agreement (May 14).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.